CTS OpTmizer T-Cell Expansion SFM is available with and without phenol red. This version of CTS OpTmizer SFM lacks phenol red, and is available in both bottle and bag format.

Features of CTS OpTmizer T-Cell Expansion SFM include:
 Supports high-density T cell culture (>4 x 106 CD3+ T-cells/mL)
 Supports T-cell activation using Dynabeads magnetic beads, soluble antibodies, and stimulatory antibody-presenting cell protocols
 Similar phenotype, function (e.g., cytokine secretion profile), and viability to T-cells cultured with conventional human AB serum-supplemented medium
 Supports a T-cell phenotype similar to human serum-supplemented medium
 Demonstrates enhanced efficacy and persistence of CART-19 cells when grown in medium supplemented with CTS Immune Cell Serum Replacement (ICSR)

Demonstrated functional performance:
Cells grown in CTS OpTmizer T-Cell Expansion SFM with or without human serum demonstrate good cytokine production profiles in polyclonally activated T cells. CTS OpTmizer T-Cell Expansion SFM maintains the desired the CD62L+ central memory T-cell phenotype.

GMP manufactured:
The primary manufacturing site for CTS OpTmizer T-Cell Expansion SFM is FDA-registered and has an ISO13485-certified quality management system. The methods and controls used for the manufacturing are in conformity with current Good Manufacturing Practices for medical devices, 21 CFR Part 820, of the regulation. Alternate manufacturing sites are available, providing risk mitigation by helping to ensure security of supply.

Versatility:
CTS OpTmizer T-Cell Expansion SFM has been widely adopted in clinical T-cell research applications including the culture of CAR T-cells. It works with multiple culture formats, including culture flasks, culture bags, and rocking bioreactor systems. CTS OpTmizer T-Cell Expansion SFM was designed to support expansion of cultured human T-cells without additional serum supplementation. Increased performance is generally observed when supplemented with CTS Immune Cell Serum Replacement.